After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
TRVI belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Trevi Therapeutics Inc is $883.49M. A total of 1.56 million shares were traded on the day, compared to an average of 2.10M shares.
In the most recent transaction, Delfini Lisa bought 312,855 shares of TRVI for 8.09 per share on Aug 27 ’25. In a previous transaction on Mar 25 ’25, SCIASCIA THOMAS sold 2,631 shares at 6.60 per share. TRVI shares that Chief Scientific Officer owns now total 221,373.
Among the insiders who sold shares, GOOD JENNIFER L disposed of 5,263 shares on Mar 21 ’25 at a per-share price of $6.58. This resulted in the President & CEO holding 213,313 shares of TRVI after the transaction. In another insider transaction, GOOD JENNIFER L bought 5,263 shares at $6.58 per share on Mar 21 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, TRVI has a high of $8.78 and a low of $2.36.
As of this writing, TRVI has an earnings estimate of -$0.1 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$0.09 per share and a lower estimate of -$0.12. The company reported an EPS of -$0.13 in the last quarter
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. TRVI’s latest balance sheet shows that the firm has $36.83M in Cash & Short Term Investments as of fiscal 2021. There were $14.63M in debt and $12.72M in liabilities at the time. Its Book Value Per Share was $1.63, while its Total Shareholder’s Equity was $17.07M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TRVI is Buy with a score of 4.75.
